Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Type and degree/number of immunophenotypic abnormalities refine multiparameter flow cytometry (MFC)-based measurable residual disease (MRD) testing in adults allografted for Acute Myeloid Leukemia (AML) in morphologic remission

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXueyan ChenOMOthus Megan

Discussion

Loading...

Member takes

Overview

Study finds that type and degree of immunophenotypic abnormalities predict poorer outcomes in adults with AML post-allograft.

Key Points

  • This research aims to evaluate how immunophenotypic abnormalities affect measurable residual disease in AML patients.
  • Examined 1,215 adults with AML or MDS/AML undergoing allografts in remission.
  • Utilized multiparameter flow cytometry to identify MRD pre-HCT.
  • Classified leukemic blasts into stem cell and non-stem cell phenotypes based on surface marker expressions.
  • 19% of patients had pre-HCT MRD with varying immunophenotype scores.
  • Patients with high total MRD immunophenotype scores experienced worse relapse-free survival and overall survival.
  • 27% of MRD positive patients had low scores, indicating similar outcomes to those without MRD.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e56fhttps://doi.org/10.1182/blood-2025-3519
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunophenotypic abnormality quantification refines multiparameter flow cytometry‐based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission2026
  2. 2Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with <scp>MDS</scp>/<scp>AML</scp> or <scp>AML</scp>2024 · 8 citations
  3. 3Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysis2026
  4. 4Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  5. 5Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations